Pharmaceutical Manufacturing Market worth $1,190.16 billion by 2030 – Exclusive Report by Precedence Research

According to Precedence Research, during the forecast period of 2022 to 2030, the global pharmaceutical manufacturing market is estimated to develop at a compound annual growth rate (CAGR) of 12.8%. The global pharmaceutical manufacturing market was valued at USD 401.67 billion in 2021, and it is predicted to exceed USD 1,190.16 billion by 2030. The study investigates several elements and their consequences on the growth of the pharmaceutical manufacturing market.

Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1191

Growth Factor

The technological advancements in the manufacturing approaches has resulted in the cost reduction and increased output of the pharmaceutical products. The increasing investments in the expansion of manufacturing facilities are propelling the pharmaceutical manufacturing market growth. The rising adoption of latest technologies like artificial intelligence (AI) and robotics is increasing the efficiency of the pharmaceutical manufacturing by reducing the wastages of resources. The ongoing progress in the personalized medicine field is offering lucrative growth opportunities to the market players. The regulatory authorities like FDA and EMA are actively participating the growth and development of the global pharmaceutical manufacturing market. The surging prevalence of various diseases like cancer, diabetes, respiratory diseases, and cardiovascular diseases is significantly driving the growth of the pharmaceutical manufacturing market owing to the burgeoning demand for various medicines across the globe.

Ask Here For More Customization Study@ https://www.precedenceresearch.com/customization/1191

This report focuses on pharmaceutical manufacturing market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall pharmaceutical manufacturing market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Latin America, etc.

The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Report Highlights:

• By drug development type, the in-house segment dominated the global pharmaceutical manufacturing market in 2019. The extensive use of the in-house infrastructure and the rising investments in the development of the in house facilities by the top pharmaceutical companies have fostered the growth of this segment.
• Based on the route of administration, the oral was the leading segment in 2019. The oral route of administration is the traditional, most convenient, and most preferred route of administration across the globe, which has resulted in its dominance across the globe.
• On the basis of formulation, the tablets segment dominated the global pharmaceutical manufacturing market in 2019. Tablets offers easy of storage and convenience is transportation. The consumers finds it much more convenient and thus the demand for the tablet forms of medicine has gained rapid traction among the consumers.
• By therapy, cancer was the largest segment in 2019. This is attributed to the increased prevalence of cancer and the high demand for the medicines to treat cancer. According to the International Agency for Research on Cancer, around 19.3 million new cases of cancer were reported and around 10 million cancer deaths were recorded in 2020 across the globe. The surging prevalence of cancer has fueled the growth of this segment and is expected to sustain the position of the segment in the foreseeable future.
• North America was the leading pharmaceutical manufacturing market in 2019. The presence of numerous top pharmaceutical companies, favorable government policies, rapid growth of the biopharmaceutical companies, and the increased investments in the research and development of medicines are the major factors behind the growth of this region. The region witnesses the presence of numerous CROs and CMOs, which contributes significantly towards the growth of the pharmaceutical manufacturing market. The US hold the majority of the property rights of the newly developed drugs. The huge demand for the various medicines owing to the increased prevalence of diseases and the high healthcare expenditure are the major factors behind the growth of the North America pharmaceutical manufacturing market.
• Asia Pacific is expected to be the fastest-growing pharmaceutical manufacturing market. The favorable government policies is attracting FDIs from the top MNCs owing to the cheap availability of the factors of production. The region is home to several top contract manufacturers which further propels the market growth.

In-Depth Analysis on Competitive Landscape

The report sheds light on leading manufacturers of pharmaceutical manufacturing, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of pharmaceutical manufacturing has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the pharmaceutical manufacturing market.

Some of the prominent players in the pharmaceutical manufacturing market include:

• GlaxoSmithKline plc
• Merck & Co., Inc.
• Eli Lilly and Company
• Johnson & Johnson
• Hoffmann-La Roche Ltd.
• Lonza
• Pfizer, Inc.
• Sanofi SA
• Novartis AG
• AstraZeneca

Segments Covered in the Report

By Drug Development Type

• In-house
• Outsource

By Route of Administration

• Topical
• Oral
• Inhalations
• Parenteral
• Others

By Formulation

• Injectable
• Tablets
• Suspensions
• Capsules
• Sprays
• Others

By Therapy

• Diabetes
• Cardiovascular Diseases
• Respiratory Diseases
• Cancer
• Pain
• Others

Regional Segmentation

• Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
• Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
• North America [United States, Canada, Mexico]
• South America [Brazil, Argentina, Columbia, Chile, Peru]
• Middle East & Africa [GCC, North Africa, South Africa]

Some of the important ones are:

• What can be the best investment choices for venturing into new product and service lines?
• What value propositions should businesses aim at while making new research and development funding?
• Which regulations will be most helpful for stakeholders to boost their supply chain network?
• Which regions might see the demand maturing in certain segments in near future?
• What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
• Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
• Which government regulations might challenge the status of key regional markets?
• How will the emerging political and economic scenario affect opportunities in key growth areas?
• What are some of the value-grab opportunities in various segments?
• What will be the barrier to entry for new players in the market?

Table of Contents

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Pharmaceutical Manufacturing Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Pharmaceutical Manufacturing Market

5.1. Covid-19: Pharmaceutical Manufacturing Industry Impact
5.2. Pharmaceutical Manufacturing Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pharmaceutical Manufacturing Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pharmaceutical Manufacturing Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Pharmaceutical Manufacturing Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing prevalence of chronic ailments
6.1.1.2. Growing geriatric population
6.1.2. Market Restraints
6.1.2.1. Stringent Regulations
6.1.3. Market Opportunities
6.1.3.1. Increasing prevalence of chronic ailments
6.1.3.2. Growing geriatric population

Chapter 7. Global Pharmaceutical Manufacturing Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pharmaceutical Manufacturing Market Revenue by Market Players (2016 -2019)
7.1.1.2. Pharmaceutical Manufacturing Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Development Type Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Pharmaceutical Manufacturing Market, By Drug Development Type

8.1. Pharmaceutical Manufacturing Market, by Drug Development Type, 2017-2030
8.1.1. In-house
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Outsource
8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Pharmaceutical Manufacturing Market, By Route of Administration

9.1. Pharmaceutical Manufacturing Market, by Route of Administration, 2017-2030
9.1.1. Topical
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Oral
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Inhalations
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Parenteral
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Pharmaceutical Manufacturing Market, By Formulation

10.1. Pharmaceutical Manufacturing Market, by Formulation, 2017-2030
10.1.1. Injectable
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Tablets
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Suspensions
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Capsules
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Sprays
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Pharmaceutical Manufacturing Market, By Therapy

11.1. Pharmaceutical Manufacturing Market, by Therapy, 2017-2030
11.1.1. Diabetes
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Cardiovascular Diseases
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Respiratory Diseases
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Cancer
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Pain
11.1.5.1. Market Revenue and Forecast (2017-2030)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Pharmaceutical Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America
12.1.1. Market Revenue Forecast by Drug Development Type(2017-2030)
12.1.2. Market Revenue Forecast by Route of Administration(2017-2030)
12.1.3. Market Revenue Forecast by Formulation (2017-2030)
12.1.4. Market Revenue Forecast by Therapy (2017-2030)
12.1.5. U.S
12.1.5.1. Market Revenue Forecast (2017-2030)
12.1.6. Canada
12.1.6.1. Market Revenue Forecast (2017-2030)
12.2. Europe
12.2.1. Market Revenue Forecast by Drug Development Type (2017-2030)
12.2.2. Market Revenue Forecast by Route of Administration (2017-2030)
12.2.3. Market Revenue Forecast by Formulation (2017-2030)
12.2.4. Market Revenue Forecast by Therapy (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue Forecast (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue Forecast (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue Forecast (2017-2030)
12.2.8. Rest of EU
12.2.8.1. Market Revenue Forecast (2017-2030)
12.3. Asia Pacific (APAC)
12.3.1. Market Revenue Forecast by Drug Development Type (2017-2030)
12.3.2. Market Revenue Forecast by Route of Administration (2017-2030)
12.3.3. Market Revenue Forecast by Formulation (2017-2030)
12.3.4. Market Revenue Forecast by Therapy (2017-2030)
12.3.5. China
12.3.5.1. Market Revenue Forecast (2017-2030)
12.3.6. India
12.3.6.1. Market Revenue Forecast (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue Forecast (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue Forecast (2017-2030)
12.4. LATAM
12.4.1. Market Revenue Forecast by Drug Development Type (2017-2030)
12.4.2. Market Revenue Forecast by Route of Administration (2017-2030)
12.4.3. Market Revenue Forecast by Formulation (2017-2030)
12.4.4. Market Revenue Forecast by Therapy (2017-2030)
12.4.5. Brazil
12.4.5.1. Market Revenue Forecast (2017-2030)
12.4.6. Rest of LATAM
12.4.6.1. Market Revenue Forecast (2017-2030)
12.5. Middle East and Africa (MEA)
12.5.1. Market Revenue Forecast by Drug Development Type (2017-2030)
12.5.2. Market Revenue Forecast by Route of Administration (2017-2030)
12.5.3. Market Revenue Forecast by Formulation (2017-2030)
12.5.4. Market Revenue Forecast by Therapy (2017-2030)
12.5.5. GCC
12.5.5.1. Market Revenue Forecast (2017-2030)
12.5.6. North Africa
12.5.6.1. Market Revenue Forecast (2017-2030)
12.5.7. South Africa
12.5.7.1. Market Revenue Forecast (2017-2030)
12.5.8. Rest of MEA
12.5.8.1. Market Revenue Forecast (2017-2030)

Chapter 13. Company Profiles

13.1. GlaxoSmithKline plc
13.1.1. Company Overview, Business Information, Regional Presence
13.1.2. Product Portfolio Analysis
13.1.2.1. Product Details, Specification, Formulation
13.1.3. Revenue, Price, and Gross Margin (2015-2020)
13.1.4. Recent Developments and Strategies
13.2. Merck & Co., Inc.
13.2.1. Company Overview, Business Information, Regional Presence
13.2.2. Product Portfolio Analysis
13.2.2.1. Product Details, Specification, Formulation
13.2.3. Revenue, Price, and Gross Margin (2015-2020)
13.2.4. Recent Developments and Strategies
13.3. Eli Lilly and Company
13.3.1. Company Overview, Business Information, Regional Presence
13.3.2. Product Portfolio Analysis
13.3.2.1. Product Details, Specification, Formulation
13.3.3. Revenue, Price, and Gross Margin (2015-2020)
13.3.4. Recent Developments and Strategies
13.4. Johnson & Johnson
13.4.1. Company Overview, Business Information, Regional Presence
13.4.2. Product Portfolio Analysis
13.4.2.1. Product Details, Specification, Formulation
13.4.3. Revenue, Price, and Gross Margin (2015-2020)
13.4.4. Recent Developments and Strategies
13.5. F. Hoffmann-La Roche Ltd.
13.5.1. Company Overview, Business Information, Regional Presence
13.5.2. Product Portfolio Analysis
13.5.2.1. Product Details, Specification, Formulation
13.5.3. Revenue, Price, and Gross Margin (2015-2020)
13.5.4. Recent Developments and Strategies
13.6. Lonza
13.6.1. Company Overview, Business Information, Regional Presence
13.6.2. Product Portfolio Analysis
13.6.2.1. Product Details, Specification, Formulation
13.6.3. Revenue, Price, and Gross Margin (2015-2020)
13.6.4. Recent Developments and Strategies
13.7. Pfizer, Inc.
13.7.1. Company Overview, Business Information, Regional Presence
13.7.2. Product Portfolio Analysis
13.7.2.1. Product Details, Specification, Formulation
13.7.3. Revenue, Price, and Gross Margin (2015-2020)
13.7.4. Recent Developments and Strategies
13.8. Sanofi SA
13.8.1. Company Overview, Business Information, Regional Presence
13.8.2. Product Portfolio Analysis
13.8.2.1. Product Details, Specification, Formulation
13.8.3. Revenue, Price, and Gross Margin (2015-2020)
13.8.4. Recent Developments and Strategies
13.9. Novartis AG
13.9.1. Company Overview, Business Information, Regional Presence
13.9.2. Product Portfolio Analysis
13.9.2.1. Product Details, Specification, Formulation
13.9.3. Revenue, Price, and Gross Margin (2015-2020)
13.9.4. Recent Developments and Strategies
13.10. AstraZeneca
13.10.1. Company Overview, Business Information, Regional Presence
13.10.2. Product Portfolio Analysis
13.10.2.1. Product Details, Specification, Formulation
13.10.3. Revenue, Price, and Gross Margin (2015-2020)
13.10.4. Recent Developments and Strategies

Chapter 14. Appendix

14.1. About Us
14.2. Glossary of Terms

Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1191

About Us

Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.

From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.

Contact Us:                  

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com